An elevated serum alkaline phosphatase level in hepatic metastases of grade 1 and 2 gastrointestinal neuroendocrine tumors is unusual and of prognostic value

被引:11
作者
Andriantsoa, Maeva [1 ]
Hoibian, Solene [1 ]
Autret, Aurelie [2 ]
Gilabert, Marine [1 ]
Sarran, Anthony [3 ]
Niccoli, Patricia [1 ,4 ]
Raoul, Jean-Luc [1 ]
机构
[1] Paoli Calmettes Inst, Dept Med Oncol, Marseille, France
[2] Paoli Calmettes Inst, Dept Biostat, Marseille, France
[3] Paoli Calmettes Inst, Dept Med Imaging, Marseille, France
[4] Aix Marseille Univ, Marseille, France
关键词
ENDOCRINE TUMORS; F-18-FDG PET; SURVIVAL;
D O I
10.1371/journal.pone.0177971
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background In our clinical practice we have observed that despite a high hepatic metastatic tumor burden, serum alkaline phosphatase (AP) levels are frequently normal in cases of metastatic neuroendocrine tumor (NET). Patients and methods We retrospectively reviewed the records of patients with grade 1 and 2 NETs with liver metastases but without bone metastases seen at our institution in 2013. In total, 49 patients were included (22 female), with a median age of 60 years (range: 28 to 84 years). The primary tumors were located in the duodenum/pancreas (n = 29), small bowel (n = 17) or colon/rectum (n = 3); 10 cases were grade 1 and 39 grade 2. Hepatic involvement was bulky, with more than 10 lesions in 23 patients and a tumor burden above 10% of the liver volume in 26 patients. Results Serum AP levels were elevated (>= upper limit of normal (ULN)) in 16 patients. In multiparametric analysis, elevated serum AP levels were not associated with the primary site, grade, or number or volume of metastases. In multiparametric analysis, progression-free survival was only correlated with grade (p = 0.010) and AP level (p = 0.017). Conclusions Serum AP levels are frequently normal in liver metastases from NET, even in the event of a major tumor burden, and the serum AP level can be of prognostic value.
引用
收藏
页数:8
相关论文
共 13 条
[1]   Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas [J].
Ambrosini, Valentina ;
Campana, Davide ;
Polverari, Giulia ;
Peterle, Chiara ;
Diodato, Stefania ;
Ricci, Claudio ;
Allegri, Vincenzo ;
Casadei, Riccardo ;
Tomassetti, Paola ;
Fanti, Stefano .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (12) :1843-1848
[2]   High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuro endocrine Tumors: A Long-Term Evaluation [J].
Bahri, Haifa ;
Laurence, Lenoir ;
Edeine, Julien ;
Leghzali, Houda ;
Devillers, Anne ;
Raoul, Jean-Luc ;
Cuggia, Marc ;
Mesbah, Habiba ;
Clement, Bruno ;
Boucher, Eveline ;
Garin, Etienne .
JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (11) :1786-1790
[3]   Standardized Uptake Values of 68Ga-DOTANOC PET: A Promising Prognostic Tool in Neuroendocrine Tumors [J].
Campana, Davide ;
Ambrosini, Valentina ;
Pezzilli, Raffaele ;
Fanti, Stefano ;
Labate, Antonio Maria Morselli ;
Santini, Donatella ;
Ceccarelli, Claudio ;
Nori, Francesca ;
Franchi, Roberto ;
Corinaldesi, Roberto ;
Tomassetti, Paola .
JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (03) :353-359
[4]  
Chou WC, 2014, ANTICANCER RES, V34, P5661
[5]   Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors [J].
Clancy, Thomas E. ;
Sengupta, Tanya P. ;
Paulus, Jessica ;
Ahmed, Fawzia ;
Duh, Mei-Sheng ;
Kulke, Matthew H. .
DIGESTIVE DISEASES AND SCIENCES, 2006, 51 (05) :877-884
[6]   Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma [J].
Durante, Cosimo ;
Boukheris, Houda ;
Dromain, Clarisse ;
Duvillard, Pierre ;
Leboulleux, Sophie ;
Elias, Dominique ;
de Baere, Thierry ;
Malka, David ;
Lumbroso, Jean ;
Guigay, Joel ;
Schlumberger, Martin ;
Ducreux, Michel ;
Baudin, Eric .
ENDOCRINE-RELATED CANCER, 2009, 16 (02) :585-597
[7]   Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors [J].
Garin, Etienne ;
Le Jeune, Florence ;
Devillers, Anne ;
Cuggia, Marc ;
de Lajarte-Thirouard, Anne-Sophie ;
Bouriel, Catherine ;
Boucher, Eveline ;
Raoul, Jean-Luc .
JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (06) :858-864
[8]   Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors [J].
Hauck, Lisa ;
Bitzer, Michael ;
Malek, Nisar ;
Plentz, Ruben R. .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (01) :55-59
[9]   Incidence and management of malignant digestive endocrine tumours in a well defined French population [J].
Lepage, C ;
Bouvier, AM ;
Phelip, JM ;
Hatem, C ;
Vernet, C ;
Faivre, J .
GUT, 2004, 53 (04) :549-553
[10]  
Onesti JK, 2015, J GASTROINTEST SURG